Antivirals for Virus Induced Exacerbations of Asthma and COPD Treatment

1. Mihailov C, Jimborean G, Rascu A, Arghir, OC. The Impact of Tobacco Smoke Exposure on Asthma COPD-Like Patients. J. Environ. Prot. Ecol. 2016;17(4), 1523-1523.Search in Google Scholar

2. Dantes E, Man MA, Arghir OA, Alexandrescu D, Trofor A. Risk factors and overlap between asthma and chronic obstructive pulmonary disease. Proceedings of the International Conference on Risk Management, Assessment and Mitigation, RIMA ‘10; WSEAS Conference Book „RECENT ADVANCES IN RISK MANAGEMENT, ASSESSMENT AND MITIGATION” Australia WSEAS Press. 2010;369-373.Search in Google Scholar

3. Rascu A, Popa DE, Arghir OC, Naghi E. Effects of Corticosteroid Treatment on Respiratory Muscles Function in Patients with Severe Obstructive Lung Disease, FARMACIA. 2016; 64(6):819-822.Search in Google Scholar

4. Biancardi E, Fennell M, Rawlinson W, Thomas PS. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital. Int. Med. J. 2016;46, 1160-1165.Search in Google Scholar

5. Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM. Prevalence of viral infection detected by PCR and RTPCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010;15, 536-542.Search in Google Scholar

6. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310:1225-1229.10.1136/bmj.310.6989.1225Search in Google Scholar

7. Edwards MR, Kebadze T, Johnson MW, Johnston SL. New treatment regimens for virus-induced exacerbations of asthma. Pulm. Pharmacol. Ther. 2006;19, 320-334.Search in Google Scholar

8. Cambrea SC, Halichidis S, Mihai CM, Carp DS, Stoicescu RM, Arghir OC. Environmental risk factors for influenza AH1N1 among children in south-east Romania, J. Environ. Prot. Ecol. 2013;14(3):1132-1139.Search in Google Scholar

9. Welte T, Miravitlles M. Viral, bacterial or both? Regardless, we need to treat infection in COPD. Eur. Respir. J. 2014;44:11-13.Search in Google Scholar

10. Saleh A, López-Campos JL, Hartl S, et al. The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit, PLos One. 2015;10(7), e0134004.Search in Google Scholar

11. López-Campos JL, Hartl S, Pozo-Rodríguez F, et al. Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit. PLos One, 2015;10(4), e0124374.10.1371/journal.pone.0124374Search in Google Scholar

12. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2001;164:1618-1623.Search in Google Scholar

13. Oliver BG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax. 2008;63:519-525.10.1136/thx.2007.081752Search in Google Scholar

14. Hendricks MR, Lashua LP, Fischer DK, et al. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. Proc. Natl, Acad. Sci. U S A, 2016;113:1642-1647.10.1073/pnas.1516979113Search in Google Scholar

15. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ, 1993;307:982-986.10.1136/bmj.307.6910.982Search in Google Scholar

16. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ. 2002;324:1-5.10.1136/bmj.324.7340.763Search in Google Scholar

17. Wark PAB, Tooze M, Powell H, et al. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology. 2013;18, 996-1002.Search in Google Scholar

18. Rewar S, Mirdha D, Rewar P. Treatment and Prevention of Pandemic H1N1 Influenza. Ann. Glob. Health. 2015;81:645-653.Search in Google Scholar

19. Pelaez A, Lyon GM, Force SD, et al. Efficacy of Oral Ribavirin in Lung Transplant Patients with Respiratory Syncytial Virus Lower Respiratory Tract Infection. J. Heart Lung Transplant, 2009;28:67-71.10.1016/j.healun.2008.10.008Search in Google Scholar

20. Liss HP, Bernstein J. Ribavirin Aerosol in the Elderly. Chest. 1998;93:1239-1241.Search in Google Scholar

21. Nathan RA, Geddes D, Woodhead M. Management of influenza in patients with asthma or chronic obstructive pulmonary disease. Ann. Allergy Asthma Immunol. 2001;87:447-454.10.1016/S1081-1206(10)62255-7Search in Google Scholar

22. Hayden FG, Belshe RB, Clover RD, et al. Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families. N. Engl. J. Med. 1989;321:1696-1702.Search in Google Scholar

23. Davies B.E. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 2010;65:ii5-ii10.10.1093/jac/dkq015283551120215135Search in Google Scholar

24. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2545.10.1136/bmj.g2545398197524811411Search in Google Scholar

25. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA. 2000;283:1016-1024.10.1001/jama.283.8.101610697061Search in Google Scholar

26. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother. 1999;44:23-29.Search in Google Scholar

27. Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547.10.1136/bmj.g2547398197624811412Search in Google Scholar

28. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza a and b infection in high-risk patients: A pooled analysis of randomized controlled trials. Arch. Intern. Med.2001;161:212-217.Search in Google Scholar

29. Wester A, Shetty AK. Peramivir injection in the treatment of acute influenza: a review of the literature. Infect. Drug Resist. 2016;9:201-214.Search in Google Scholar

30. Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. J. Antimicrob. Agents Chemother. 2010; 54(11):4568-4574.10.1128/AAC.00474-10297617020713668Search in Google Scholar

31. Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin. Infect. Dis. 2010;51:1167-1175.Search in Google Scholar

32. Smee DF, Tarbet EB, Furuta Y, et al. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol. 2013;8:1085-1094.10.2217/fvl.13.98392931024563658Search in Google Scholar

33. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446-454.10.1016/j.antiviral.2013.09.015388083824084488Search in Google Scholar

34. Berry CM. Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System. Cytokine Growth Factor Rev. 2016;31:83-90.10.1016/j.cytogfr.2016.08.00127544015Search in Google Scholar

35. Kim S, Kim MJ, Kim CH, et al. The Superiority of IFN-lambda as a Therapeutic Candidate to Control Acute Influenza Viral Lung Infection. Am. J. Respir. Cell Mol. Biol. 2017; 56(2):202-212.Search in Google Scholar